Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/S0140-6736(23)00555-X | DOI Listing |
Lancet Respir Med
December 2024
Unit of Pharmacology, Department of Experimental Medicine, University of Campania 'Luigi Vanvitelli', Naples, Italy.
Lancet Respir Med
December 2024
Late-stage Development, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK. Electronic address:
Lancet Respir Med
December 2024
School of Pharmacy, Faculty of Medical and Health Sciences, The University of Auckland, Auckland, New Zealand.
Lancet Infect Dis
November 2024
Manchester Fungal Infection Group, University of Manchester, Manchester, UK. Electronic address:
Background: Despite antifungal treatment, chronic pulmonary aspergillosis (CPA) is associated with substantial morbidity and mortality. We conducted a systematic review and meta-analysis to evaluate rates of mortality and its predictors in CPA.
Methods: A systematic literature search was conducted across MEDLINE (PubMed), Scopus, Embase, and Web of Science to identify studies in English, reporting mortality in CPA, from database inception to Aug 15, 2023.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!